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Abstract
Background: Preclinical toxicity of adaphostin has been related to oxidative stress. This study investigated the 
regulatory mechanism underlying adaphostin induction of heme oxygenase 1 (HMOX1) which plays a significant role 
in modulation of drug-induced toxicity in the non-small cell lung cancer cell line model, NCI-H522.
Methods: The transcriptional response of NCI-H522 to adaphostin prominently involved oxidative stress genes, 
particularly HMOX1. Reactive oxygen species (ROS) involvement was additionally established by generation of ROS 
prior to modulation of adaphostin-toxicity with antioxidants. To identify up-stream regulatory elements of HMOX1, 
immunofluorescence was used to evaluate nuclear translocation of the transcription factor, NF-E2-related factor 2 
(Nrf2), in the presence of adaphostin. The PI3-kinase inhibitor, wortmannin, was employed as a pharmacological 
inhibitor of this process.
Results: Generation of ROS provided a substantial foundation for the sensitivity of NCI-H522 to adaphostin. However, 
in contrast to leukemia cell lines, transcriptional response to oxidative stress was associated with induction of HMOX1, 
which was dependent on nuclear translocation of the transcription factor, Nrf2. Pretreatment of cells with wortmannin 
inhibited translocation of Nrf2 and induction of HMOX1. Wortmannin pretreatment was also able to diminish 
adaphostin induction of HMOX1, and as a consequence, enhance the toxicity of adaphostin to NCI-H522.
Conclusions: Adaphostin-induced oxidative stress in NCI-H522 was mediated through nuclear translocation of Nrf2 
leading to upregulation of HMOX1. Inhibition of Nrf2 translocation by wortmannin inhibited this cytoprotective 
response, and enhanced the toxicity of adaphostin, suggesting that inhibitors of the PI3K pathway, such as 
wortmannin, might augment the antiproliferative effects of adaphostin in solid tumors that depend on the Nrf2/ARE 
pathway for protection against oxidative stress.
Background
Adaphostin (NSC 680410) is the adamantyl ester of tyr-
phostin AG957 (NSC 654705) and inhibits the p210bcr-
abl tyrosine kinase in CML, but is also toxic against cells
without the fusion protein[1]. The toxicity of adaphostin
against leukemia cells has been shown to require genera-
tion of reactive oxygen species (ROS) [2] and involve iron
homeostasis [3], and most work on this compound has
focused on hematologic malignancies. However, in vitro
testing of adaphostin in the NCI-60 cell line panel indi-
cated that several solid tumor cancer cell lines also dem-
onstrated considerable sensitivity to adaphostin,
indicating there may be a role for adaphostin in treatment
of solid tumors. The prostate tumor cell line, PC3 was
published as a model to demonstrate signaling cascades
involved in adaphostin induced growth inhibition and
cell cycle arrest [4], but this cell line is an order of magni-
tude more resistant than the lung tumor model NCI-
H522 to the growth inhibitory effects of the drug in the
NCI-60 human tumor cell line screen (data on DTP web-
site: http://dtp.nci.nih.gov/). An early report showed an
anti-tumor effect on an orthotopic glioblastoma model
U87, in combination with the Flt-1/Fc chimera [5], and
more recent evaluation of adaphostin activity in glioblas-
toma cell lines identified a high level of HMOX1 induc-
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tion [6]. HMOX1 is the first and rate limiting step in the
degradative pathway of heme, but has also been recog-
nized as an integral part of a cytoprotective mechanism
against oxidative stress [7,8]. HMOX1 is a target gene of
the basic leucine zipper (bZIP) transcription factor,
nuclear factor erythroid 2-like 2, Nrf2 (NFE2L2), a central
regulator of cellular oxidative stress response and repre-
sents an adaptive response that increases cell resistance
to oxidative injury. Nrf2 is readily induced in response to
ROS through the Nrf2-ARE pathway which transcrip-
tionally up regulates antioxidant genes in order to protect
cells [9]. Nrf2 is regulated through PI3K/AKT pathway
[10-12], and translocated into the nucleus where it binds
to the antioxidant responsive element (ARE) which
results in activation of this enhancer element and initiates
the transcription of genes encoding phase II detoxifica-
tion enzymes. These enzymes [8,9] initiate an antioxidant
response, which can be beneficial for cancer prevention
[13]. However, the Nrf2-ARE pathway has recently been
implicated in chemoresistance and the feasibility of Nrf2
inhibition as a strategy for sensitizing cells to chemother-
apeutics was demonstrated [13-15]. HMOX1 upregula-
tion has been identified in the adaphostin response in
adherent cell lines, but not in hematopoietic cell line
models, and it appears that adaphostin activates a differ-
ent oxidative stress response in solid tumor models than
in leukemia models. Thus, we have investigated the
mechanism behind HMOX1 induction in the adaphostin-
sensitive lung tumor cell line NCI-H522, and demon-
strated an enhancement of adaphostin toxicity following
inhibition of Nrf2 nuclear translocation with the PI3K
inhibitor wortmannin.
Methods
Drugs and Cell Culture
Adaphostin (NSC 680410) and wortmannin (NSC
221019) were obtained from the repository of the
National Cancer Institute's Developmental Therapeutics
Program (Rockville, Maryland). Desferrioxamine (DFX)
and N-acetyl-cysteine (NAC) were purchased from
Sigma® (St. Louis, Missouri). NCI-H522, and the leukemia
cell lines, (Jurkat, HL60 and K562) were obtained from
the NCI-60 Human Tumor Cell Line Screen (National
Cancer Institute-Frederick, Maryland).
Transcriptional Profiling: Microarray Technology
Human OperonV2, 20K arrays, (National Cancer Insti-
tute microarray facility/Advanced Technology Center,
Gaithersburg, Maryland) were utilized according to pub-
lished protocols http://madb.nci.nih.gov/. Using compet-
itive hybridization of treated versus untreated samples
chemically coupled to a Cy™3 or Cy™5 fluorescently
labeled dye (Amersham Biosciences, Little Chalfont
Buckinghamshire, England) and fluorescence was read on
a GenePix 4100A microarray scanner purchased from
Axon Instruments (Union City, California). Data was ana-
lyzed using the Axon GenePix Pro 4.1 software and data
and image files were then uploaded to the National Can-
cer Institute/Cancer Center for Research Microarray
Center mAdB Gateway for analysis and comparison of
multiple arrays.
Real Time RT-PCR
Five hundred nanograms of total RNA for each sample
was reverse transcribed using the GeneAmp® PCR System
9700 and TaqMan® Reverse Transcription Reagents kit.
Quantitative real time PCR reactions were conducted and
measured using the ABI Prism™ 7700 Sequence Detection
System and TaqMan® chemistries using published prim-
ers. Samples were tested in triplicate wells for the genes
of interest and for the endogenous control, 18 S. Data was
analyzed using the comparative Ct method as described
in the Perkin Elmer User Bulletin #2 (ABI Prism® 7700
Sequence Detection System, 1997) and expressed as a
fold induction of the gene in the adaphostin treated sam-
ples compared to the untreated control samples, and sig-
nificant differences were calculated using a paired two
sample t-test.
Western Blot
Whole cell and nuclear extracts were made for protein
analysis by western blot. Nuclear extracts were prepared
from cells in 100 mm dishes that were lysed using a hypo-
tonic buffer. The nuclei were pelleted at 13,000 × g for 15
minutes, and then after the supernatant was aspirated,
the nuclei were lysed using 1x RIPA lysis buffer (Upstate,
Lake Placid, New York) containing protease inhibitors
(Roche, Mannheim, Germany). Protein was quantitated
using Bradford Protein Assay (Bio-Rad Laboratories,
Hercules, California), and approximately 50 μg of each
sample was resolved by SDS-PAGE on 10% Tris glycine
gels (Invitrogen, Carlsbad, California) and probed with
anti-Nrf2 (Santa Cruz Biotechnology, Santa Cruz, Cali-
fornia) and anti-HMOX1 antibodies (Affinity BioRe-
agents, Golden, Colorado). Proteins were visualized using
chemiluminescence and imaged using a Kodak™ X-
OMAT 2000A Processor (Rochester, New York).
Measurement of adaphostin-induced ROS
Intracellular ROS were measured after 2 and 4 hours
exposure to 1 μM adaphostin using 2',7'-dichlorofluores-
cein diacetate (DCFH-DA, Sigma®, St. Louis, Missouri).
Cells were incubated for 3 minutes with 10 μM DCFH-
DA, lysed and centrifuged. The fluorescence was read on
a Wallac Victor 2 I420 Multilabel Counter (PerkinElmer,
Waltham, Massachusetts) at excitation of 485 nm and
emission of 535 nm and protein normalized using Brad-
ford Protein Assay. Results were expressed as percentageFer et al. Journal of Experimental & Clinical Cancer Research 2010, 29:91
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increase compared to control and significant differences
calculated using a two sample t-test assuming equal vari-
ances.
Modulation of growth inhibition
Cells were inoculated onto 96 well plates (20,000 cells/
well) and preincubated with DFX (100 μM), NAC (25
mM) or wortmannin (250 nM) prior to addition of ada-
phostin for a further 96 h incubation. Growth inhibition
was assessed by alamarBlue (Sigma®, St. Louis, Missouri),
fluorescence was read on a Tecan Ultra plate reader (509
nm excitation and 520 nm emission); and results ana-
lyzed using the average percent treated/control (%T/C),
with significant differences calculated using a paired two
sample t-test.
Immunofluorescence
Cells were plated in Lab-Tek chamber slides (60,000 cells/
well) and treated 4-6 hours with 1 μM adaphostin, or pre-
treated 30 minutes with 500 nM wortmannin, followed by
4 hour incubation with 1 μM adaphostin where indicated.
Cells were fixed using cold methanol; permeabilized with
0.1% Triton X-100; blocked in 20% goat serum; incubated
with Nrf2 antibody overnight; labeled using FITC-conju-
gated secondary antibody; and nuclei were counter-
stained with DAPI. Prolong Anti-Fade (Invitrogen, Carls-
bad, California) was used to mount coverslip overnight.
Samples were visualized using a Leitz Laborlux D fluores-
cence microscope and images were captured by Leica
DFC420 camera and analyzed in Adobe Photoshop Ele-
ments 2.0.
Results
Although hematopoietic malignancies have been the
major target of pre-clinical studies with adaphostin [1-
3,5,16-19], NCI-H522, a solid tumor-derived, non-small
lung cancer cell line, was also very sensitive to adaphostin
in the NCI-60 human tumor cell line screen. From four
independent experiments in the NCI-60 screen, the 50%
growth inhibitory concentration (GI50) for the 6 leuke-
mia cell lines ranged from 40 nM -630 nM, and the GI50
for NCI-H522 was 79 nM, which was 10-fold more sensi-
tive than the average response for the whole cell line
panel (762 nM) (data available at: http://dtp.nci.nih.gov/
for NSC 680410). Transcriptional profiling of NCI-H522
in response to 1 μM adaphostin showed one of the most
highly upregulated genes to be HMOX1 (11.3 +/- 2.1 (SD)
fold increase after 24 h), which encodes for an enzyme
that protects against oxidative stress [7,8]. This increase
in HMOX1 expression was confirmed using Q-RT/PCR
which also corroborated the lack of significant change in
expression of the NRF2 gene (figure 1A). Moreover, a
small but significant increase in the Nrf2 transcriptional
target gene, NAD(P)H dehydrogenase, quinone 1 NQO1
was observed although there was no change in another
Nrf2 target, the catalytic subunit of glutamate-cysteine
ligase GCLC (figure 1A). A significant increase in ROS
production was observed as early as 2 h after adaphostin
treatment which is confirmation of the presence of drug-
induced oxidative stress (figure 1B). Heme oxygenase 1,
the protein encoded by HMOX1, was shown to be
increased by adaphostin treatment (1 μM) at a later time
point than HMOX1, being only slightly increased after 6
h, but highly expressed after 24 h (figure 1C). These data
are consistent with the 10 μM adaphostin-induced heme
oxygenase 1 expression reported in glioblastoma cell
lines, which did not appear until after 8-24 h [6]. This
adaphostin-induced HMOX1 upregulation in NCI-H522
cells and glioblastoma cell lines [6] is in contrast to the
response of hematologic cell lines where we have previ-
ously reported the major transcriptional response
involved >10-fold induction of genes encoding for both
heavy and light ferritin polypeptides (FTH and FTL) [3].
Moreover, even after treatment with 10 μM adaphostin,
Figure 1 Adaphostin (ADA) effect on HMOX1 related genes, ROS, 
and HMOX1 protein. (A) ADA modulation of NRF2, HMOX1, GCLC, 
and NQO1 gene expression. Cells were treated with 1 μM of ADA for 1, 
6 and 24 h and gene expression was measured by microarray and 
quantitative RT/PCR and expressed as fold change of drug -treated 
NRF2, HMOX1, GCLC, and NQO1 compared with control (n = 4; +/- SD). 
Both HMOX1 and NQO1 were significantly up-regulated by ADA (** p 
< 0.01). (B) Increased ROS production after ADA treatment. Cells were 
treated for 2 and 4 h with 1 μM ADA and ROS was measured using 
DCFH-DA (10 μM). There was a significant increase in ADA-induced 
ROS production. After 2 and 4 h (n = 2 +/- SD, * p < 0.05). (C) ADA in-
duces HMOX1 protein. NCI-H522 cells were incubated for 2 h, 4 h and 
6 h with 1 μM of ADA and whole cell extracts were resolved by Western 
blot analysis as indicated in the Materials and Methods. Data are repre-
sentative of three independent experiments.
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leukemia cell lines (Jurkat, HL60 and K562) showed no
increase in HMOX1 expression on the cDNA arrays after
6 h incubation (average expression (n = 3) = 1.24 +/-
0.7(SD), 1.35 +/- 0.39(SD) and 1.16 +/- 0.28(SD) respec-
tively), compared to a 7.4 and 30.8 -fold increase in
HMOX1 expression in NCI-H522 cells when measured
on the same type of arrays following treatment with 1 and
4 μM adaphostin for 6 h. Evidence that ROS are an
important factor in determining sensitivity of NCI-H522
to adaphostin was demonstrated by the ablation of ada-
phostin toxicity by the anti-oxidant, N-acetyl-cysteine in
a manner similar to that shown for the leukemia cell line
Jurkat (figure 2). However, in contrast to Jurkat, the iron
chelating agent desferrioxamine (100 μM) did not attenu-
ate adaphostin toxicity in the NCI-H522 cell line (figure
2), and there was no measurable increase in either ferritin
gene (array expression (n = 5): FTH = 1.09 +/- 0.15 (SD);
FTL = 1.02 +/- 0.24(SD)), indicating that release of excess
free iron is not involved in the NCI-H522 response to
adaphostin. Thus, these data substantiate the difference
between response of a solid tumor and that which we
have shown in leukemia cell lines [3].
As the induction of HMOX1 appears to be unique to
the response of solid tumors [6], we investigated the role
of its putative regulatory transcription factor, Nrf2, in
adaphostin treated NCI-H522 cells. Nrf2 protein, when
activated is rapidly translocated into the nucleus, and in
adaphostin-treated NCI-H522 cells, Nrf2 was rapidly
induced in the nuclear fraction within 2-6 h, although
there was no detectable Nrf2 expression in the cytosolic
fraction over this time (figure 3A). Furthermore, translo-
cation of Nrf2 from the cytoplasm into the nucleus by
adaphostin can be visualized using immunohistochemis-
try (figure 3B) where nuclear localization of Nrf2 after 4 h
and 6 h incubation of NCI-H522 cells with 1 μM ada-
phostin was apparent compared to the more diffuse Nrf2
distribution in untreated cells.
Wortmannin, a PI3 kinase inhibitor, has been shown to
inhibit Nrf2 translocation into the nucleus [20,21] and
was successfully used as a tool to inhibit adaphostin-
induced, nuclear translocation of Nrf2 (figure 4). Pre-
treatment (30 minutes) of NCI-H522 cells with 500 nM
wortmannin was effective at inhibiting adaphostin-
induced nuclear localization of Nrf2, although wortman-
nin alone had no effect. In addition, under these condi-
tions when Nrf2 translocation was inhibited with
wortmannin, expression of Nrf2 target genes HMOX1
and NQO1were significantly (p < 0.01) reduced by ~50%
and ~35% respectively after 6 h adaphostin incubation,
and though not significant, there was a trend to a reduced
expression after 4 h incubation (figure 5). There was no
significant change in GCLC expression which is consis-
tent with the lack of induction of this gene with adaphos-
tin, and implicates Nrf2 as the regulator of adaphostin-
induced HMOX1.
Finally, figure 6 shows that when HMOX1 induction
was diminished via inhibition of Nrf2 nuclear transloca-
tion, there was an augmentation of adaphostin toxicity
with a reduction of the GI50 from 342 nM to 273 nM, with
the most significant effect (p < 0.01) at the lower concen-
trations of adaphostin.
Discussion
Adaphostin, is a tyrphostin-like kinase inhibitor whose
toxicity to tumor cell lines is a function of its ability to
induce oxidative stress and cause a redox imbalance in
cells [2,22-25]. In hematologic tumor cell lines, we have
previously shown that iron homeostasis and up-regula-
tion of ferritin genes were an integral part of the response
to adaphostin [3]. In contrast, evaluation of the transcrip-
tional response of a solid tumor derived, non-small cell
lung cancer cell line, NCI-H522, which is equally sensi-
tive to adaphostin as the hematologic cell lines indicated
Figure 2 The presence of ROS is an important factor in determin-
ing sensitivity to adaphostin (ADA). (A) Dose response curves of 
NCI-H522 after treatment with ADA either alone or in combination 
with 25 mM n-acetyl cysteine (NAC) or 100 μM desferrioxamine (DFX). 
ADA sensitivity was attenuated by NAC, but not DFX (n = 3; +/- SD). (B) 
Dose response curves of Jurkat after treatment with ADA either alone 
or in combination with 25 mM NAC or 100 μM DFX. ADA sensitivity was 
attenuated by NAC and DFX (n = 3; +/- SD).
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that the HMOX1 gene was the most highly up-regulated
gene, and there was very little modulation of the ferritins.
The up-regulation of HMOX1 in solid tumor derived
models, is consistent with data published for glioblas-
toma cell lines [6] suggesting that these cell lines may uti-
lize different pathways to handle the adaphostin induced
oxidative stress. Moreover, the growth inhibitory curve of
adaphostin in NCI-H522 was completely ablated by pre-
treatment with the antioxidant NAC, but not with desfer-
rioxamine indicating that despite the role of HMOX1 in
generating free iron from heme, iron homeostasis is not
an important feature of the response to ROS generated by
adaphostin. HMOX1 is a stress-inducible enzyme that is
Figure 3 Adaphostin (ADA) induces nuclear localization of Nrf2 protein. (A) NCI-H522 cells were incubated for 2 h, 4 h and 6 h with 1 μM of ADA; 
nuclear and cytosolic proteins were resolved by Western blot analysis as indicated in the Materials and Methods (NS, non-specific band was used for 
normalization). Data are representative of three independent experiments. (B) Confirmation of ADA-induced Nrf2 translocation into the nucleus. NCI-
H522 cells were incubated for 4 h or 6 h with 1 μM ADA and were stained with Nrf2 and FITC-conjugated antibodies. Nuclei were counter-stained with 
the fluorescence dye DAPI. Data are representative of three independent experiments.
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Figure 4 Wortmannin inhibits adaphostin (ADA)-induced trans-
location of Nrf2 into the nucleus. NCI-H522 cells were pretreated 30 
minutes with 500 nM wortmannin where indicated, followed by 4 hour 
incubation with 1 μM ADA and stained with Nrf2 and FITC-conjugated 
antibodies. Nuclei were counter-stained with the fluorescence dye DA-
PI. Data are representative of two independent experiments.
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Figure 5 Adaphostin (ADA) induction of HMOX1 and NQO1 is in-
hibited by the presence of wortmannin (WTM). NCI-H522 cells were 
pretreated 30 minutes with 500 nM WTM, followed by incubation with 
1 μM ADA. Expression of HMOX1, NQO1 and GCLC was measured by 
quantitative real-time reverse transcription-PCR after a further 1, 4 and 
6 h and expressed as a percentage of the control ADA-induced gene 
expression measured at that time in the absence of WTM pretreat-
ment. There was a significant decrease in 6 h ADA-induced HMOX1 
and NQO1expression after wortmannin pretreatment (n = 3; +/- SD; ** 
indicates p < 0.01)
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most commonly regulated by the basic leucine zipper
transcription factor Nrf2, which is a regulator of multiple
antioxidant genes [12]. Dramatic induction of HMOX1
appears to be stimulated by adaphostin in this cell line.
Another well documented target of Nrf2, NAD(P)H
dehydrogenase, quinone 1 (NQO1) was also induced to a
lesser extent but there was no evidence for regulation of
gamma-glutamylcysteine synthetase (GCLC), which is
consistent with data from cultured RPE cells where mod-
ulation of Nrf2 activity led to selective down regulation of
only certain phase 2 detoxification genes, and not all
stimuli resulted in all genes being modulated [11].
Adaphostin triggered the translocation of Nrf2 protein
i n t o  t h e  n u c l e u s ,  a s  m e a s u r e d  b o t h  b y  a n  i n c r e a s e  i n
nuclear protein and immunofluorescence. Nrf2 translo-
cation into the nucleus has been shown to be prevented
by the PI3 kinase inhibitor, wortmannin [11,21]. Pretreat-
ment with wortmannin was clearly able to reduce ada-
phostin-induced Nrf2 nuclear translocation in NCI-
H522, and there was a significant decrease in HMOX1
induction after 6 h adaphostin treatment. Thus, these
data confirm in a sensitive solid tumor model, NCI-H522,
that the major cause of adaphostin toxicity was through
generation of ROS, which is the widely accepted model of
toxicity for hematologic malignancies [2,3,25]. However,
unlike hematologic malignancies, adaphostin initiated an
antioxidant response in NCI-H522 cells through up-regu-
lation of HMOX1. The transcriptional increase was initi-
ated through Nrf2, following its translocation into the
nucleus, and could be inhibited by wortmannin, implicat-
ing the PI3K pathway in the activity of adaphostin. Nrf2
has been identified as a master redox switch involved in
the activity of cytoprotective phytochemicals with
chemopreventive activity against cancer [26], and plays
an important role in the defense against oxidative stress
[27]. However, a 'dark side' of Nrf2 has recently been rec-
ognized [15], identifying it as responsible for resistance
against chemotherapy, thus making Nrf2 a potential tar-
get to improve activity of certain chemotherapeutic
agents [13,28,29].
Conclusions
Targeting of the Nrf2 transcription factor may be impor-
tant for drugs whose major mechanism of action was
through the generation of ROS (e.g. adaphostin), as there
is evidence for a selective killing of tumor versus normal
cells [30], and inhibition of the antioxidant, protective
role of Nrf2 may increase the toxic potential of such
agents. When NCI-H522 cells were preincubated with
wortmannin to inhibit Nrf2 translocation, there was a
significant increase in adaphostin toxicity. This data may
provide a rationale for successful combinations of ada-
phostin, or other pro-oxidant agents, with inhibitors of
the PI3K pathway as modulators of Nrf2 antioxidant
activity.
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